Elucidation of the Mechanisms and Molecular Targets of Sanhuang Xiexin Decoction for Type 2 Diabetes Mellitus Based on Network Pharmacology

Abstract EN

Sanhuang Xiexin Decoction (SXD) is commonly used to treat type 2 diabetes mellitus (T2DM) in clinical practice of traditional Chinese medicine (TCM).

In order to elucidate the specific analysis mechanisms of SXD for T2DM, the method of network pharmacology was applied to this article.

First, the effective ingredients of SXD were obtained and their targets were identified based on the TCMSP database.

The T2DM-related targets screened from the GEO database were also collected by comparing the differential expressed genes between T2DM patients and healthy individuals.

Then, the common targets in SXD-treated T2DM were obtained by intersecting the putative targets of SXD and the differential expressed genes of T2DM.

And the protein–protein interaction (PPI) network was established using the above common targets to screen key genes through protein interactions.

Meanwhile, these common targets were used for GO and KEGG analyses to further elucidate how they exert antidiabetic effects.

Finally, a gene pathway network was established to capture the core one in common targets enriched in the major pathways to further illustrate the role of specific genes.

Based on the data obtained, a total of 67 active compounds and 906 targets of SXD were identified.

Four thousand one hundred and seventy-six differentially expressed genes with a P value < 0.005 and ∣log2fold change∣>0.5 were determined between T2DM patients and control groups.

After further screening, thirty-seven common targets related to T2DM in SXD were finally identified.

Through protein interactions, the top 5 genes (YWHAZ, HNRNPA1, HSPA8, HSP90AA1, and HSPA5) were identified.

It was found that the functional annotations of target genes were associated with oxygen levels, protein kinase regulator, mitochondria, and so on.

The top 20 pathways including the PI3K-Akt signaling pathway, cancers, HIF-1 signaling pathway, and JAK-STAT signaling pathway were significantly enriched.

CDKN1A was shown to be the core gene in the gene-pathway network, and other several genes such as CCND1, ERBB2, RAF1, EGF, and VEGFA were the key genes for SXD against T2DM.

Based on the network pharmacology approach, we identified key genes and pathways related to the prognosis and pathogenesis of T2DM and also provided a feasible method for further studying the chemical basis and pharmacology of SXD.